PIK3CA and cancer: In detail, PIK3CA mutations are described in >10% of cancer patients and have been recognized as pathogenetic in many solid tumors such as breast, endometrial, bladder, colorectal, and head and neck squamous cell carcinoma, as well as in other benign skin lesions (e.g., epidermal nevi) [17,21].